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 ABSTRACT 
The therapeutic targeting of intrinsically disordered proteins (IDPs) by small molecules has been a chal-
lenge due to their heterogeneous conformational ensembles. A potential therapeutic strategy to alleviate 
the aggregation of IDPs is to maintain them in their native monomeric state by small molecule binding. 
This study investigates the structural basis of small molecule druggability of native monomeric Tau 
whose aggregation is linked to the onset of Tauopathies such as Alzheimer’s disease. Initially, two avail-
able monomeric conformational ensembles of a shorter Tau construct K18 (also termed Tau4RD) were 
analyzed which revealed striking structural differences between the two ensembles, while similar num-
ber of hot spots and small molecule binding sites were identified on monomeric Tau ensembles as on 
tertiary folded proteins of similar size. Remarkably, some critical fibril forming sequence regions of Tau 
(V306-K311, V275-K280) participated in hot spot formation with higher frequency compared to other 
regions. As an example of small molecule binding to monomeric Tau, it was shown that methylene blue 
(MB) bound to monomeric K18 and full-length Tau selectively with high affinity (Kd = 125.8 nM and 
86.6 nM, respectively) with binding modes involving Cys291 and Cys322, previously reported to be 
oxidized in the presence of MB.  Overall, our results provide structure-based evidence that Tau can be a 
viable drug target for small molecules and indicate that specific small molecules may be able to bind to 
monomeric Tau and influence the way in which the protein interacts among itself and with other pro-
teins. 
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INTRODUCTION 
Tauopathies1 are a subset of neurodegenerative disorders, including Alzheimer’s disease (AD)2 and 
frontotemporal dementias (FTD)3, which are linked to the accumulation of neurofibrillary tangles 
(NFTs) that are formed by the aggregation of microtubule associated protein Tau (MAPT) in patients’ 
brain cells. The aggregation of monomeric Tau in neurons leads to the instability of microtubules in the 
axons, and the presence of Tau oligomers and fibrils generated through its aggregation cause toxic ef-
fects in neurons resulting in neurodegeneration. 
Intrinsically disordered proteins (IDP) such as the Tau protein have been considered as intractable 
drug targets for small molecule drug discovery due to the lack of a stable 3D structure. Therefore Tau 
has been neglected by most small molecule drug discovery programs and has been mostly targeted by 
specific monoclonal antibodies for immunotherapy4-5.  Since Tau is an intra-cellular protein localized 
mostly in neurons, it is not clear whether antibody-based drug development efforts will lead to effica-
cious treatments. Moreover, the economic cost of a potential immunotherapy for tens of millions of pa-
tients with Tauopathies will not likely be affordable for our society. Therefore, it is critical to explore 
alternative small molecule approaches targeting the Tau protein for the development of disease modify-
ing therapeutics. 
The soluble monomeric state of Tau has been studied by NMR spectroscopy6-9, which showed that the 
structure of monomeric Tau is made up of a diverse conformational ensemble. This conformational en-
semble is not completely random: some pronounced intramolecular interactions exist and some regions 
have some propensity to adopt defined secondary structure6-9.  
Computational structure-based modeling approaches are applied to generate conformational ensem-
bles of IDPs, which use experimentally derived observations such as NMR, small-angle X-ray and 
FRET experimental data10. Two main approaches exist for generating conformational ensembles, the so-
called pool-based and the molecular dynamics (MD) based approach.  Typically, the extent and resolu-
tion of the experimental data is not sufficient for either approach to generate accurate high resolution 3D 
structures.  Recently, two conformational ensembles of the monomeric form of Tau have been pub-
lished6, 11.  
We have previously explored whether small molecule binding pockets can exist within members of the 
heterogeneous conformational ensemble of IDPs despite their overall lack of persistent structures. Our 
results from investigating monomeric α-synuclein12 and Aβ42 peptide13 suggest that locally persistent 
binding sites are present even within a diverse population of conformations of these proteins. Moreover, 
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a recent analysis of publicly available conformational ensembles of some IDPs found that IDPs have a 
comparable number of potential binding sites as proteins with ordered 3D tertiary structure14.  
Binding of small molecules to such pockets may have distinct effects such as altering the conforma-
tional ensemble of IDPs and possibly impacting the dynamics and thermodynamic stability of the vari-
ous conformational states12.  The basis of the binding mechanism of small molecules to IDPs is yet to be 
clearly elucidated, nevertheless it has been assumed that it involves conformational selection by the 
binding ligand12-13, 15.  Consequently, targeting the conformational ensemble of the apo form of IDPs 
could be a viable structure-based drug discovery strategy. We previously successfully applied this ap-
proach for the basis of a structure-based computational docking screen on the conformational ensemble 
of α-synuclein to identify novel fragment and drug-like small molecules targeting monomeric α-
synuclein, one of which was active in cellular models of α-synuclein-mediated dysfunction12. In another 
recent study, novel compounds binding to c-Myc were identified by structure-based virtual screening on 
three binding pockets of representative c-Myc conformations16. 
Only a limited number of small molecule ligands of monomeric Tau have been described in the litera-
ture17-18.  Most of the identified compounds are, however, suboptimal for further drug discovery optimi-
zation, as they have either non-druglike physicochemical properties or contain reactive functional 
groups that are frequently associated with toxicity issues and lack of specificity19-21. Recently, we ap-
plied a unique biophysics based binding screening methodology to detect the binding between small 
molecules and monomeric Tau, which led to the identification of a diverse set of novel fragment and 
lead-like small molecules capable of interacting with Tau, some of which were able to reduce the aggre-
gation of Tau in vitro and in a cellular model of Tauopathies22. The study demonstrates that monomeric 
Tau can be a viable receptor of small drug-like molecules, and supports the potential and practical feasi-
bility of the therapeutic strategy to target early phases of the aggregation pathway of Tau and potentially 
other IDPs by small molecules, thereby eliminating the formation of potential toxic misfolded protein 
species.  This and other studies suggest that the structure-based identification of novel small molecules 
binding to IDPs, such as monomer Tau, could be a viable drug discovery strategy23. 
One of the most studied Tau interacting ligand is methylene blue (MB) (Fig. S1), an approved treat-
ment for methemoglobinemia, which has been shown to have a wide range of interacting protein part-
ners and biological activities24.  MB was shown to inhibit Tau aggregation25 and to disintegrate Tau fi-
brillar aggregates. In particular, Taniguchi et al. showed that MB inhibits heparin-induced Tau filament 
formation (IC50 = 1.9 µM)
26.  Thionine (a desmethyl derivative of MB) showed inhibition of Tau-Tau 
binding (IC50 = 98 nM)
25. MB also promoted the oxidation of the cysteine residues of Tau (C291 and 
C322), to sulfenic (SO), sulfinic (SO2) and sulfonic (SO3) forms, in vitro, and thus presumably inhibit 
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the aggregation of the protein by retaining it in an oxidized monomeric conformation27-28. Interestingly, 
MB also inhibited caspase 1 and 3 activities in vitro through the oxidization of their catalytic cysteine29.  
Moreover, MB protected from Tau over-expression caused neurotoxicity in vivo30-31 and MB based ther-
apeutic candidate, LMTX® (TauRx’s second-generation Tau aggregation inhibitor (TAI)), has been 
through several phase 3 clinical trials in AD and is still under investigation in further phase 3 clinical 
trials in AD. 
We set out to continue to investigate the small molecule targetability of IDPs, by focusing on Tau pro-
tein. Small molecules may have the potential to bind to specific conformations of monomeric Tau that 
could influence the way in which Tau interacts among itself and with other proteins in neurons. Thus, 
binding small molecules to monomeric Tau could alter its aggregation propensity, or perturb the mal-
function or the toxicity in neurons caused by Tau aggregation, or influence Tau modulated signal trans-
duction. In this study, we characterized the structural diversity and availability of small molecule bind-
ing sites within two published conformational ensembles of Tau and analyzed their applicability to ra-
tional drug design. Moreover, we investigated binding ability of MB to monomeric Tau as a model sys-
tem for Tau interactions using computational structure based and biophysical experimental approaches. 
Our results yield further insights on the applicability of available IDP conformational ensembles, exist-
ence of binding sites, and provide a better understanding of the targetability of monomeric Tau by small 
molecules.   
 
RESULTS 
Characterization of monomeric Tau ensembles 
The two publicly available 3D structural ensembles of monomeric K18 Tau, comprising the repeat 
domain responsible for aggregation, were collected and analyzed to assess their structural diversity and 
their potential applicability for structure-based drug discovery.  Ensemble 1 (ENS#1) was reported by 
Ozenne et. al.6 consisting of 801 Tau conformers at high resolution, and the second ensemble 2 (ENS#2) 
was reported by Fisher et. al.11 containing 75 conformers. 
Both Tau ensembles were found to be substantially diverse because the closest internal conformers 
had a root-mean-square deviation (RMSD) of 11.28 Å (ENS#1) and 9.26 Å (ENS#2), respectively. The 
overall diversity of the individual ensembles was similar when all RMSD matrix elements were consid-
ered (average RMSD) (Fig. 1A), while the minimum RMSD of each conformer to its closest neighbor 
(minimum RMSD) was larger for ENS#2 (Fig. 1B), which may be attributed to the lower ensemble size 
of ENS#2. 
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Figure 1. RMSD distribution curves of monomeric Tau ensembles ENS#1 (blue), ENS#2 (red) and the 
combined ensemble (green) calculated for all RMSD matrix elements (average RMSD) (A) and between 
each conformer and their closest conformer (minimum RMSD) (B). Distribution of the number (Nb) of 
intramolecular contacts in monomeric Tau ensembles ENS#1 (blue) and ENS#2 (red): number of H-
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bonds (C), number of “Good” contacts (D), number of “Bad” (E) and number of “Ugly” (F) contacts 
(see definitions in Methods).   
 
Surprisingly, when the two ensembles were combined, the closest conformers in the combined set had 
an RMSD of 9.26 Å (as in ENS#2) exposing that the two ensembles contain significantly different con-
formations. (The full RMSD matrices are shown in Fig. S2).  To assess the compactness of the conform-
ers, intramolecular contacts were calculated. Interestingly, many more van der Waals contacts (“Good”, 
“Bad” and “Ugly” – see definitions in Methods) were found in ENS#1, while ENS#2 contained more H-
bonds (Fig. 1C-F).  To further assess the compactness of the ensembles, the radii of gyration (Rg) of the 
conformers were calculated. ENS#1 had lower Rg value distribution in line with the higher number of 
van der Waals contacts (Fig. S3).  The secondary structural content of the conformers was calculated, 
which indicated that some regions show higher propensity of helical and β-sheet secondary structures 
(Fig. 2A and 2B). 
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Figure 2. Distribution of helical (A) and β−sheet (B) secondary structure content in monomeric Tau 
ensembles ENS#1 (blue) and ENS#2 (red). Regions of higher secondary structure propensity are marked 
by green circles. Hot spot formation propensity (C) of residues in monomeric Tau ensembles ENS#1 
(blue) and ENS#2 (red). Fibril-forming regions (V306-K311 and V275-K280) are indicated by larger 
markers / dashed lines. 
 
In particular, the secondary structure analysis suggested higher propensity for nascent helices between 
residues L284-N286 and L315-K317 and increased propensity for β-structured conformation between 
residues G271-Q276. This latter region coincides with the V275-K280 sequence that has been shown to 
play a critical role in forming the core of Tau fibrils32-34. Moreover, the P270-G273 region has been sug-
gested to form a β-hairpin conformation35. Unexpectedly, the two ensembles feature completely differ-
ent secondary structure elements: helical structures were solely found in ENS#1, while β structures were 
only present in ENS#2 (Fig. 2A and 2B). 
Small molecule binding site mapping 
Next, all Tau conformers were mapped for the presence of potential hot spots and small molecule 
binding sites using FTMap36. The mapping results revealed that the intrinsically disordered monomeric 
state of Tau contained similar number of binding hot spots (Fig. 3A and 3B) and binding sites (Fig. 3C) 
as the investigated folded proteins with tertiary structure. 
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Figure 3. Distribution of the number (Nb) of strong binding hot spots (A), number (Nb) of all binding 
hot spots (B) and binding sites (C) in monomeric Tau ensembles ENS#1 (blue) and ENS#2 (red) and 
folded proteins (green) (see definitions of strong hot spots and binding sites in Methods). Binding hot 
spot examples (black circles) on selected Tau conformations (D).  
 
In particular, the distribution of strong hot spots (see definition in Methods) that are essential for bind-
ing site formation was almost identical for ENS#1 and ENS#2 as for folded proteins (Fig. 3A). Moreo-
ver, the Tau ensembles contained more weak hot spots and an approximately similar number of binding 
sites compared to folded tertiary proteins (Fig. 3). Solvent accessible surface area (SASA) of the hot 
spots showed similar distribution for ENS#1 and ENS#2 (Fig. S4).  
The tendency of individual residues to form binding hot spots was also analyzed. The two most criti-
cal fibril forming regions of Tau, the hexapeptide motifs V306-K311, V275-K280, are among the most 
frequently occurring residues in forming the hot spots (Fig. 2C). In particular, the V306-K311 region 
formed hot spots with highest propensity in ENS#1 and second highest in ENS#2. These results suggest 
that the monomeric structural ensembles of Tau investigated contain hot spots and targetable small mol-
ecule binding sites, which indicates that intrinsically disordered Tau may be a tractable target for small 
molecule drug discovery.   
Investigation of the monomeric Tau binding characteristics of methylene blue 
To elucidate further the interaction between MB with Tau, we investigated whether MB can oxidize 
cysteines in general by using glutathione (GSH), as standard model molecule generally used in covalent 
drug discovery37 with the aim to gain insights into the thiol oxidation reactivity of MB. Our experiments 
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showed that MB does not form any covalent complexes with GSH, however, it facilitates the oxidation 
of GSH (Fig. 4A). 
 
 
Figure 4. Oxidation kinetics of glutathione (GSH) in the presence (red) and absence (blue) of methylene 
blue (MB) monitored by LC-MS (A). Standard deviation is indicated by error bars. Dose-response curve 
between GSH and MB based on measured microscale-thermophoresis shows that no direct interaction 
could be detected (B). The fluorescence of MB was exploited for the MST experiments. 
 
Given that GSH is a small flexible peptide, it is unlikely that MB has a specific affinity to GSH driven 
by non-bonded interactions. To elucidate this we tested whether GSH binds to MB using microscale 
thermophoresis (MST). The strong fluorescence properties of MB (Excmax: 665 nm; Emmax: 692 nm) 
enables its label-free application as a sensitive molecular interaction detection system in MST. The MST 
experiments showed no sign of the existence of detectable interaction between MB and GSH (Fig. 4B).  
This suggests that the oxidation of GSH by MB was driven by diffusional effects. 
Next, this MST set-up was further applied to characterize the affinity of MB to monomeric Tau. The 
concentration-dependent change in thermophoresis and T-jump signals indicated that MB binds both to 
monomeric full-length (Fig. 5A) and to monomeric K18 Tau with Kd values of 86.6 ± 8.8 nM and 125.8 
± 5.4 nM (Fig. 5B), respectively, whereas MB bound only weakly to BSA (Kd > 1 µM) (Fig. 5C). 
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Figure 5. Dose-response curve between MB and monomeric full-length Tau (A), K18 Tau (B) and bo-
vine serum albumin (C) based on measured combined Tjump and microscale thermophoresis data. 
 
Overall, these results suggest that MB binds to monomeric Tau with reasonably high affinity and with 
some specificity, and this binding is non-covalent by nature. Consequently, MB herein will be used as a 
model ligand to evaluate the targetability of monomeric Tau ensembles by structure-based docking of 
small molecules.   
Exploration of the binding site of methylene blue to monomeric Tau 
To identify the potential binding sites of MB to monomeric Tau, we applied structure-based docking 
calculations to each of the predicted small molecule binding sites of the Tau conformations from both 
ensembles. All possible binding modes of MB generated by the docking program FRED were rank or-
dered by a consensus scoring scheme (see Methods for details), which provided a rank of the predicted 
binding modes of MB to Tau. The distribution of the consensus ranks is plotted in Fig. 6. 
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Figure 6. Distributions of the ranks of MB binding modes to the binding sites of monomeric Tau en-
sembles ENS#1 (blue) and ENS#2 (red).  
 
Several potential binding modes of MB at different binding sites of monomeric Tau were identified in 
both Tau ensembles. The docking results indicated more favorable binding of MB to Tau conformations 
in ENS#1 compared to ENS#2 (Fig. 6). Binding conformations in close proximity of C291 and C322 
were selected as these residues were suggested to be directly involved in MB binding on the basis of 
NMR HSQC measurements and the oxidation of both cysteine residues due to MB28.  206 MB binding 
poses were identified, where either C291 or C322 was found within 6 Å proximity of MB. Out of these 
206 binding poses, 9 (8.0% hit rate) belonged to ENS#1 and 197 (17.7% hit rate) to ENS#2, respective-
ly (Fig. S5). 
These MB binding modes were ranked by the consensus docking ranks and the highest ranked 10% 
(21) of the poses were selected for further analysis. In the 21 selected poses ENS#2 was over-
represented: 20 poses (1.8%) from ENS#2 compared to 1 pose (0.9%) from ENS#1. In one of the 21 
finally selected docking poses MB was found within 6 Å from both C291 and C322 (Fig. 7A and 7B). 
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A       B 
  
 
 
 
C       D 
  
Figure 7. Predicted binding poses of MB in selected representative conformations of K18 of Tau. Bind-
ing pose #4 (A, B): MB is in close proximity to both C291 and C322. Binding pose #1 (C, D): highest 
ranked binding pose of MB by consensus scoring (Coloring scheme is the following: C291 and C322 in 
orange, fibril forming region V306-K311 in green and nascence helical regions L284-N286 and L315-
K317 in magenta). 
 
The highest ranked binding mode of MB is shown in Fig. 7C and 7D. In both binding modes the fibril 
forming V306-K311 region as well as the nascent helical regions (L284-N286 and L315-K317) contrib-
uted to binding site formation. All interacting residues are listed in Table S1. 
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In summary, we identified potential binding sites and modes of MB to Tau, using previous experi-
mental results28 demonstrating that structure-based modeling can be applied on conformational ensem-
bles of monomeric Tau.  This suggests that such approach may be also useful for the development of 
Tau targeting small molecule therapeutic candidates.  
 
DISCUSSION AND CONCLUSION 
Comparison of two distinct monomer Tau conformational ensembles 
While both Tau conformational ensembles analyzed satisfy the global experimental parameters of 
monomeric Tau according to their authors, striking structural differences were identified between the 
two ensembles. In particular, the closest conformers between ENS#1 and ENS#2 were more dissimilar 
than the closest conformers in ENS#2 (RMSD = 9.26 Å). In other words, the conformations of the two 
ensembles had significantly different RMSD at the global level, although this does not exclude the pos-
sibility of local similarities. In line with the RMSD differences, the internal contact profiles of the two 
ensembles also differed substantially. Moreover, nascent helical and β-sheet structures were unevenly 
distributed in the two ensembles: helical structures were solely found in ENS#1, while β-sheet struc-
tured conformations were only captured by ENS#2. 
Plausible explanations for these striking differences in the two ensembles may be the followings. The 
level of disorder in monomeric Tau has been particularly high and the acquisition of relevant experi-
mental data that can be translated to structural constraints is limited in extent and resolution. Therefore 
multiple possible conformational ensembles can be generated that satisfy the limited number of experi-
mental constraints. The sampling of both reported ensembles may be insufficient, as they are selected to 
satisfy all constraints by the smallest possible set of conformers. In addition, more, relevant experi-
mental data that can be translated to local structural constraints and utilized during ensemble generation 
are needed. In particular, it has been suggested that novel techniques capable of sampling proteins on a 
longer timescale would be required for a better characterization of IDPs38. 
Nevertheless, in both cases, the individual conformations of the published ensembles may represent 
relevant, energetically favored conformations of monomeric Tau that can be targeted by structure-based 
drug discovery. The results of this study suggest that the folding of different segments of Tau is required 
for the formation of the binding site and the complete monomeric Tau structure is not required for ac-
commodating small molecule ligands.  We also made similar observation when studying the conforma-
tional ensemble of intrinsically disordered α-synuclein12 and Aβ4213. Similarly to the α-synuclein 
study12, we identified similar number of hot spots and binding sites on the ensembles compared to ran-
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domly selected folded proteins possessing tertiary structure suggesting that it is feasible to identify high 
affinity ligands to Tau and that this may be a general character of IDPs. 
Remarkably, we found that some critical fibril forming regions (V306-K311, V275-K280) of Tau par-
ticipated in hot spot formation with higher frequency compared to other sequence regions. These re-
gions may be particularly relevant when targeting Tau with small molecules as they could potentially 
block fibril formation by competing with other Tau interacting surfaces that are critical for aggregation. 
On the binding mechanism of MB to Tau 
To demonstrate the applicability of the available conformational ensembles of Tau for structure-based 
drug discovery, we selected MB and predicted its potential binding mode to Tau.  To establish the MB – 
Tau complex as a validated model system for this study, we further explored its mechanism of interac-
tion between MB and monomeric Tau in vitro. MB has been shown to bind to monomeric Tau previous-
ly28. 
The interaction of MB with monomeric Tau is complex.  MB has been shown to be able to oxidize 
cysteine residues of monomeric Tau27-28. However, this is likely a non-specific event, as we show that 
MB can oxidize solvent accessible cysteines on a small molecule as GSH. Nevertheless, we observed 
concentration-dependent change in thermophoresis of MB when either full-length or K18 Tau was ad-
ministered. In contrast, no such changes were observed in the thermophoresis of MB when GSH was 
administered to it instead of Tau. This suggests that MB binds to monomeric Tau reversibly via non-
bonded interactions. The docking simulations of MB revealed potential binding modes that are in rea-
sonably good agreement with the available experimental data. In particular MB was found to bind in 
close proximity of C291 / C322 which were shown to be oxidized during MB administration28.  
 
Small molecule binding sites exist on monomeric Tau 
Our study of monomeric Tau structural conformational ensembles supports the results of our previous 
theoretical studies on α-synuclein12 and Aβ4213 ensembles in regard to the existence of small molecule 
binding sites on these IDPs. Our results in this study on the mechanism of binding of MB to Tau provide 
further experimental and theoretical evidence for the existence of bindings sites on Tau. Additional evi-
dence of this was demonstrated by our previous study22 in which we applied a biophysics-based high 
throughput screen to identify small molecule binders to monomeric full length Tau. A diverse set of 
novel fragment and lead-like small molecules were capable of binding monomeric Tau, some of which 
had also the ability to inhibit Tau aggregation. Overall, these results demonstrate that despite its hetero-
geneous conformational ensemble and a lack of stable tertiary structure, Tau can be a viable receptor for 
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small drug-like molecules. These findings have strong relevance to other IDPs in general and imply that 
other IDPs may also have the ability to interact with drug-like small molecules. Our results imply that 
specific small molecules may exist that could bind to monomeric Tau and influence the way in which 
Tau interacts among themselves and with other proteins in neurons. These small molecules therefore 
could alter the aggregation propensity of Tau and/or perturb Tau mediated cellular signal transduction.  
 
METHODS 
Structural data sources 
Conformational ensembles of monomeric K18 Tau were collected from the PED database 
(http://pedb.vib.be/)39 (ENS#1) and from the supplementary material of the research article of Fisher et 
al. (http://www.rle.mit.edu/cbg/data.htm)11 (ENS#2). Initial ENS#1 ensemble contained 995 structures. 
After superposition and backbone RMSD calculations 194 duplicate structures were eliminated resulting 
in 801 structures (referred as ENS#1 throughout the manuscript). ENS#2 contained 75 individual struc-
tures that represents conformations with at least 0.0005 calculated probability. All 75 structures were 
found unique after superposition and backbone RMSD calculations. 
X-ray structures of proteins with identical length of K18 Tau (130 residues), with a maximum 30% 
sequence identity were selected from the PDB database [http://www.rcsb.org]. Ten (PDB IDs: 1KNM, 
2NWD, 3FYM, 3RFE, 4ESP, 4HWM, 4PS6, 4XPX, 4YTK, 5C6S) out of the 53 resulting structures 
were selected based on the resolution of the structures.  
RMSD matrix calculations 
Tau structures were superimposed by their C-alpha atoms and backbone RMSD matrices were calcu-
lated for both ensembles in Maestro40 using Conformer Cluster. 
Prediction of side chain conformations 
Original version of ensemble ENS#1 lacked side chain conformations. RASP41 was used by default 
parameters to calculate the missing side chains for ENS#1.  
Molecular contacts calculation 
Intramolecular contacts were calculated and classified in Maestro40 as follows:  H-bonds: H...A dis-
tance must be less than 2.8 Å, the D-H...A angle must be greater than 120°, and the H...A–B angle must 
be greater than 90°. 
Contacts are defined by a ratio given by the following formula: 
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C = D12 / (R1 + R2) 
where D12 is the distance between atoms 1 and 2, and R1 and R2 are the van der Waals radii of atoms 1 
and 2. The contacts are classified into “Good”, “Bad”, and “Ugly” based on this ratio. The default val-
ues are: Good: 1.30 > C > 0.89; Bad: 0.89 > C > 0.75; Ugly: C < 0.75. 
Secondary structure calculation 
Per residue secondary structure was determined for all conformations of monomeric Tau by DSSP 
(http://swift.cmbi.ru.nl/gv/dssp)42 with default parameters. 
Binding site mapping 
The FTMap web server36 (http://ftmap.bu.edu/) was used to identify binding hot spots and binding 
sites on the Tau conformers and selected folded proteins. According to the authors’ instructions43 “strong 
hot spot” was defined as a hot spot with a cross-cluster population > 16. Additionally, a “binding site” 
was defined as a minimum set of two hot spots (one of which is a strong hot spot) within 8 Å distance. 
Solvent accessible surface area of each hot spot was calculated in Maestro40 using Create Binding Site 
Surfaces panel including residues within 5 Å of a single cross-cluster (set of docked solvent molecules 
by FTMap). 
Ligand preparation 
3D conformations of methylene blue (MB) were calculated by OMEGA44-45 by applying more thor-
ough settings than default (strictfrags (true), sampleHydrogens (true), ewindow (20.0), maxconfs 
(10,000), maxtime (600.0), rms (0.3)). QUACPAC46 was used to calculate am1bcc charges for each con-
former (option: am1bccsym). 
Molecular docking 
Tau conformations were prepared for docking by using the pdb2receptor function of OEDocking47-50. 
Binding sites were defined based on the cross-clusters (set of docked solvent molecules by FTMap). 
Docking was carried out by FRED51 applying special parameters allowing a more thorough sampling 
and optimization (exhaustive_scoring (chemgauss3), rstep (0.75), tstep (0.5), num_poses (10,000), 
clash_scale (0.75), opt (chemgauss3), hitlist_size (1,000,000), num_alt_poses (100), 
sort_by_top_consensus_pose (true). Consensus pose selection was carried out using the following scor-
ing functions and weights: pose_select_weight_shapegauss 1, pose_select_weight_plp 1, 
pose_select_weight_chemgauss3 1, pose_select_weight_oechemscore 1, 
pose_select_weight_screenscore 1. Consensus scoring was applied by combining the following scoring 
functions: shapegauss, plp, chemgauss3, oechemscore, screenscore. 
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Tau Protein Preparation 
The human Tau constructs were expressed in pNG2 vector, a derivative of pET-3a (Merck-Novagen, 
Darmstadt) in E.coli strain BL21(DE3) (Merck-Novagen, Darmstadt)52. The expressed protein was puri-
fied from bacterial extract by making use of the heat stability of Tau protein. The cell pellet was resus-
pended in the boiling-extraction buffer (50 mM MES, 500 mM NaCl, 1 mM MgCl2, 1 mM EGTA, 5 
mM DTT, pH 6.8) complemented with protease inhibitor coctail (1 mM PMSF, 1 mM EDTA, 1 mM 
EGTA, 1 mM benzamidin, 1 µg/ml leupeptin, 1 µg/mL aprotinin, and 1 µg/ml pepstatin). The cells were 
disrupted with a French pressure cell and subsequently boiled for 20 min. The soluble extract was iso-
lated by centrifugation, the supernatant was dialyzed against the cation exchange chromatography buffer 
A (20 mM MES, 50 mM NaCl, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.1 mM PMSF, pH 6.8) and 
loaded on cation exchange SP-Sepharose column (GE Healthcare). The protein was eluted by a linear 
gradient of cation exchange chromatography buffer B (20 mM MES, 1 M NaCl, 1 mM EGTA, 1 mM 
MgCl2, 2 mM DTT, 0.1 mM PMSF, pH 6.8). The short Tau constructs representing Tau repeat domains 
Tau3RD (3 repeats; (M)Q244-S372 lacking V275-S305, comprising 99 residues) were subsequently 
concentrated and rebuffered in PBS (pH 7.4) on Amicon Ultra-15 device (Millipore, Bedford, MA). 
Protein concentration was determined by the Bradford assay and the purity of the proteins was analyzed 
by SDS-PAGE (17%). 
Microscale thermophoresis 
Interactions between methylene blue (MB) and K18 or full-length Tau as well as between MB and 
glutathione (GSH) were characterized by microscale thermophoresis (MST) on a Monolith NT.115 in-
strument from Nanotemper as follows. The concentration of the fluorescent MB was kept constant at 
100 nM and the concentration of proteins was increased in the samples during the MST experiments 
from 0 to 1400 nM. The proteins were dissolved in 10 mM HEPES, 5 mM NaCl, 0.005 % Tween 20 
buffer solutions at pH = 7.4. 5 µl of the respective samples were filled in MST capillaries by simple 
capillary forces. The following stages are recorded for each sample: fluorescence signal before turning 
the IR laser on, thermophoresis of molecules and back diffusion after switching the laser off. The signal 
was recorded in all capillaries at varying concentration of the non-fluorescent protein. Samples were 
incubated at 25 °C within the capillaries for 30 min prior to running measurements. Assays were con-
ducted at 40 % IR-laser power and MST powers (corresponding to the excitation strength of the LED) 
of 20%. Any change of thermophoretic properties is observed as a change in fluorescence intensity. The 
thermophoresis signal is plotted against the ligand concentration to obtain a dose-response curve, from 
which the binding affinity (Kd) can be deduced. 
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LC-MS 
Oxidation kinetics of glutathione (GSH) (Sigma, St. Louis, MO, USA) were measured by LC-MS as 
follows. GSH was dissolved in PBS buffer at a final concentration of 250 µM. 4 mM Indoprofen (Sig-
ma, St. Louis, MO, USA) was dissolved in MeCN and added as a control for UV detection. Reduced 
GSH was detected in the presence or absence of 5 mM MB after 4, 8, 12, 24, 48 and 144 hours of incu-
bation. Eluent A contained 10 mM ammonium-formate dissolved in 95% distilled water and 5% MeCN. 
Eluent B contained 10 mM ammonium-formate dissolved in 20 % distilled water and 80 % MeCN. The 
gradient was changed from 0 % to 100 % B in 1 min then hold 100 % B for 2.5 min and changed gradu-
ally to 0 % B in 1.5 min and hold at 0 % for 0.5 min. The operating conditions were as follows: nebuliz-
er gas: 1.5 L/min; drying gas: 15 L/min; temperature of desolvation lines: 300 °C; temperature of col-
umn: 30 °C; time of measurement: 5 min; ionization: DUIS; recorded m/z range: 50-1000; column: 
WATREX rs15.9e.s1003, Reprospher 100 C18, 5 µm, 100x3 mm; instrument: Shimadzu LCMS-2020 
Statistics 
To assess the significance of the differences between the distributions we applied Kolmogorov-
Smirnov test, which is a nonparametric test to compare two distributions with different sample sizes as 
well as two sample, independent Student t-tests. Statistical analysis was carried out by XLSTAT53. 
 
SUPPLEMENTARY INFORMATION (SI) 
SI contains supplementary material on the structural characterization of Tau conformational ensembles 
and on the description of the binding sites of MB on monomeric Tau. 
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